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Abstract
Background: Alkaptonuria is a rare, debilitating autosomal recessive disorder affecting tyrosine metabolism. Deficiency
of homogentisate 1,2-dioxygenase leads to increased homogentisic acid which is deposited as ochronotic pigment.
Clinical sequelae include severe early onset osteoarthritis, increased renal and prostate stone formation and cardiac
complications. Treatment has been largely based on analgaesia and arthroplasty. The National Alkaptonuria Centre in
Liverpool has been using 2 mg nitisinone (NTBC) off-license for all patients in the United Kingdom with alkaptonuria and
monitoring the tyrosine metabolite profiles.
Methods: Patients with confirmed alkaptonuria are commenced on 2 mg dose (alternative days) of NTBC for three
months with daily dose thereafter. Metabolite measurement by LC-MS/MS is performed at baseline, day 4, three-months,
six-months and one-year post-commencing NTBC. Thereafter, monitoring and clinical assessments are performed
annually.
Results: Urine homogentisic acid concentration decreased from a mean baseline 20,557mol/24 h (95th percentile
confidence interval 18,446–22,669mol/24 h) by on average 95.4% by six months, 94.8% at one year and 94.1% at two
year monitoring. A concurrent reduction in serum homogentisic acid concentration of 83.2% compared to baseline was
also measured. Serum tyrosine increased from normal adult reference interval to a mean SD of 594 184mol /L at
year-two monitoring with an increased urinary excretion from 103 81mol /24 h at baseline to 1071 726mol /24 h
two years from therapy.
Conclusions: The data presented represent the first longitudinal survey of NTBC use in an NHS service setting and
demonstrate the sustained effect of NTBC on the tyrosine metabolite profile.
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Introduction
Alkaptonuria (AKU, OMIM: 203,500) is a rare auto-
somal recessive disorder resulting from mutations in the
gene that encodes for the enzyme homogentisate 1, 2-
dioxygenase (HGD, E.C.1.12.11.5).1,2 The enzyme, a
1Department of Clinical Biochemistry and Metabolic Medicine, Liverpool
Clinical Laboratories, Royal Liverpool University Hospitals Trust,
Liverpool, UK
2Bone and Joint Research Group, Musculoskeletal Biology, University of
Liverpool, Liverpool, UK
Corresponding author:
Anna M Milan, Department of Clinical Biochemistry and Metabolic
Medicine, Liverpool Clinical Laboratories, Royal Liverpool and
Broadgreen University Hospital Trust, Liverpool L7 8XP, UK.
Email: anna.milan@rlbuht.nhs.uk
Annals of Clinical Biochemistry
2017, Vol. 54(3) 323–330





constituent part of the tyrosine degradation pathway
converts homogentisic acid (HGA) to maleylacetoace-
tic acid (Figure 1). Deﬁciency of the enzyme results in
the accumulation of HGA in tissues and excretion of
gram quantities of HGA in the urine.3–6 Through ancil-
lary pathways, HGA oxidizes to benzoquinone acetic
acid (BQA), which is responsible for the black appear-
ance of urine in AKU, upon standing. The conversion
of BQA to melanin-like pigment and its binding to con-
nective tissues are linked to the destructive nature of the
disease such as seen in cartilage, bone and other con-
nective tissues such as sclera.7–12 This ochronotic pro-
cess takes place over several years and aﬀects virtually
all connective tissues.
Treatment of the condition is largely via analgesics,
joint replacement when required, dietary protein
restriction and large doses of vitamin C, each with vary-
ing degrees of eﬃcacy.11 There have been trials of 2 -(2-
nitro-4-triﬂuoromethylbenzoyl)-1,3-cyclohexanedione
(NTBC) more commonly referred to as nitisinone, in
the treatment of AKU. NTBC inhibits 4-hydroxyphe-
nylpyruvate dioxygenase (HPPD, E.C.1.13.11.27), the
enzyme which produces HGA (Figure 1).3,13
NTBC has been licenced for the treatment of heredi-
tary tyrosinaemia type 1 (HT1, OMIM 276700) since
2002 where deﬁciency of fumarylacetoacetate hydroxy-
lase (FAH, E.C. 3.7.1.2) results in liver failure, hepato-
cellular carcinoma and renal tubular dysfunction.14 The
eﬃcacy of the therapy has resulted in NTBC replacing
liver transplant as the treatment of choice in HT1.15,16
Previously published studies where NTBC has been
used in the treatment of AKU have demonstrated the
eﬀect on blocking HGA production (Table 1), all
showing> 94% reduction in urinary HGA. In all stu-
dies, the concurrent rise in plasma tyrosine was evident
with concentrations rising from within the reference



















Figure 1. Tyrosine degradation pathway indicating enzyme defect in alkaptonuria and where nitisinone acts upon the pathway.
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More recently, a large-scale international trial (suit-
ability of nitisinone in AKU 1, SONIA-1,
DevelopAKUre, project number: 304985) demon-
strated the short-term eﬀects of various doses of
NTBC (1, 2, 4 and 8mg) over a four-week period.3 A
clear, dose-dependent suppression of HGA was mea-
sured with a mean reduction of urine HGA concentra-
tion at four weeks, of 98.8% compared with baseline,
on an 8mg daily dose.
In 2012, the Robert Gregory National AKU Centre
(NAC) was established by the NHS Highly Specialised
Services Commissioning Group at The Royal Liverpool
University Hospital, UK. With recognition that NTBC
has potential for treatment of this debilitating condi-
tion, the centre aimed to provide NTBC, oﬀ-label, for
all patients in the UK with AKU. The NAC is the ﬁrst
centre to provide long-term supportive and potentially
disease-modifying medical care. This includes specialist
dietary monitoring and biochemical assessment to
ensure the safe and eﬃcacious use of NTBC.
The present publication is an audit of the service at
the NAC from a biochemical viewpoint. The NTBC is
being used oﬀ-licence in a health service setting and the
data described documents the eﬀect of NTBC on tyro-
sine metabolites over two years of usage.
Patients and methods
Patients
The protocol for treatment is that patients with con-
ﬁrmed AKU are commenced on a 2mg dose of NTBC,
on alternative days for the ﬁrst three months, which is
then increased to 2mg daily thereafter. Assessments are
repeated on an annual basis to monitor response to
therapy.
This longitudinal survey reports the biochemical data
obtained from monitoring markers of the tyrosine meta-
bolic pathway and includes data from patients that have
attended the NAC for two years (three annual visits). To
date 58 patients have enrolled at the NAC. Inclusion
criteria are diagnosis of AKU; resident of either
England or Scotland, and be aged over 16 years; exclu-
sion criteria are pregnancy and lactation. NTBC is used
in an open-label protocol here to investigate its safety
and eﬃcacy in the treatment of this rare disease. All
patients are provided with written information about
the scope of the centre and the assessments they will
receive. All patients at the NAC are assessed at baseline
with a four-day visit and then at annual follow-up. Most
patients are medically ﬁt enough to travel to Liverpool
for assessments and treatments. Metabolite measure-
ments are performed at baseline, day four (two-days
post-NTBC), three months, six-months and one-year,
with annual monitoring thereafter. Conﬁrmed diagnosis
of AKU is based upon increased urinary HGA excretion
and is mandatory for referral to the NAC. Urine HGA
excretion in healthy volunteers has been demonstrated in
the order of< 2.91mol/24 h.19
Data collection
The NAC and all subsequent data collection and analyses
are approved by The Royal Liverpool and Broadgreen
University Hospital Trusts Audit Committee (Audit no.
ACO3836). This is not a clinical trial and therefore ethical
approval is not required. Data obtained follow standard
clinical assessments upon referral to the NAC. Patients
are informed verbally and through patient information
leaﬂets about the activities of the NAC. Patients are
also explicitly informed that data may be used for publi-
cation and within the NAC patient information leaﬂet the
following paragraph is included:
We could publish results from the study but if we do,
we will make sure that you cannot be identiﬁed in
anyway. All data used for publicity or for other
research purposes will ensure total anonymity. Please
let us know when you are visiting the NAC that you
understand and have no objections to this.
No patient has objected to the use of their data.
Table 1. Summary of previous clinical trials using nitisinone in alkaptonuria.










9 0.35–1.05 mg twice
daily
3 months 94% Reduction in HGA
Introne et al.5 Randomized, parallel
group, single blind
20 No treatment, 2 mg
once daily
36 months >95% Reduction in HGA
Ranganath et al.3 Randomized, open label,
parallel-group design
40 No treatment, 1, 2, 4,
8 mg once daily
4 weeks 98.8% Reduction in HGA
on 8 mg dose
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Sample collection
Baseline 24-h urine collection (acidiﬁed with 25mL
2.5mol/L H2SO4) and serum samples were collected.
Serum samples were acidiﬁed by deproteinization with
perchloric acid (5.8mol/L). This stabilizes the HGA for
short- and long-term storage and analysis (unpublished
data).
Urine HGA and tyrosine analysis
Urine samples were analysed using a previously pub-
lished liquid chromatography tandem mass spectrom-
etry (LC-MS/MS) method.4 The only modiﬁcation was
change from d2 to a d4-tyrosine internal standard. In
brief, all analysis were performed on an Agilent 6490
Triple Quadrupole mass spectrometer with Jet-Stream
electrospray ionization coupled with an Agilent 1290
Inﬁnity II UHPLC pump and autosampler.
Ten microliters of sample were diluted 1:1000 with
0.4mol/L 13C6-HGA and 2mol/L d4-tyrosine in
0.1% formic acid (v/v) in deionized water. Separation
was achieved on an Atlantis dC18 column
(100 3.0mm, 3m, Waters) maintained at 35C.
Quantitation was achieved using a matrix matched
seven-point calibration curve and two product ion tran-
sitions for each analyte of interest (HGA 167> 122 and
167> 108, negative ionization; tyrosine 182> 136 and
182> 91 positive ionization). The urine assay was linear
for HGA concentrations up to 16mmol/L (pre-NTBC
therapy) and the lower limit of quantiﬁcation (LLOQ)
was 3mol/L (post-NTBC therapy). Dilution integrity
was assessed with recovery 96.6 6.6% (n¼ 6) on a 1 in
10 dilution, when required.4
Serum HGA, tyrosine and NTBC analysis
Serum samples were analysed on a single method for all
three analytes20 using a matrix matched serum calibra-
tion curve. As for the urine assay, all analyses were
performed by LC-MS/MS with 10L of deproteinized
sample diluted 1:1000 with 0.2mol/L 13C6-HGA,
2mol/L d4-tyrosine and 2 nmol/L
13C6-NTBC in
0.1% formic acid/deionized water. Internal standards
were lower than those used in the urine assay to reﬂect
the lower concentrations in serum, compared with
urine, requiring a more sensitive assay. Tyrosine was
linear from 10 to 2000mol/L covering both pre-
NTBC and post-NTBC concentrations within one
assay.
Creatinine measurement
Our group has published data demonstrating the inter-
ference of HGA on enzymatic creatinine assays and
assays which utilize a peroxidase reaction.21 Urine
and serum creatinine analyses were therefore performed
using the Jaﬀe creatinine assay where creatinine forms a
yellow-orange complex with picrate at an alkaline pH
measured on a Roche Cobas c501 analyser.
Statistical analysis
All statistical analyses were carried out using GraphPad
Instat. A two-tailed unpaired t-test was used to make
statistical comparison between groups to establish if
there were any signiﬁcant diﬀerences. Testing for
Gaussian distribution was performed using
Kolmogorov and Smirnov test. If data were not nor-
mally distributed, a non-parametric Mann–Whitney
test was performed to determine if there were any sig-
niﬁcant diﬀerences. Both the t-test and the Mann–
Whitney test assume equal standard deviations in the
groups; due to the large concentration changes upon
commencing NTBC, standard deviations are not the
same when comparing time points against baseline
data; therefore, an un-paired t-test with Welch correc-
tion has been applied.
Results
Patient demographics
To date (December 2015), 58 patients with AKU have
been enrolled at the NAC for treatment with NTBC.
Twenty-three females (mean age 53 years, range 22–75)
and 35 males (mean age 48 years, range 22–70). This is
an on-going service and at the time of submission for
publication, 28 patients had reached two years of moni-
toring and were included in this survey. The remaining
30 patients have had less than two years of monitoring
and were not included. One of the 28 patients included
was already on NTBC prior to enrolling at the NAC.
The average results at baseline of all NAC patients are
with the exclusion of this patient; subsequent time
points include this subjects’ data (Table 2).
Compliance issues
At both six months and one year, one patient has
become non-compliant, evidenced by undetectable
serum NTBC concentration and urine HGA increasing
to pre-treatment concentrations. The data are not
included in the overall statistics.
Urine HGA concentrations
Urine HGA excretion, in relation to 24-h excretion
(determined by volume) is shown in Figure 2(a) and
Table 2. At baseline, the average HGA excretion per
day (u-HGA24) was 20,557mol/24 h (95th percentile
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Figure 2. (a) Urine HGA excretion (mol/24 h) demonstrating the reduction in HGA excretion with oral administration of NTBC.
(b) Serum tyrosine (mol/L) demonstrating rapid increase in serum tyrosine upon commencing NTBC. Boxplot represents 95%
confidence intervals, line is median, tail the minimum and maximum results (excludes outliers). Diamond is mean and 95% confidence
intervals (includes outliers). X¼ outliers> 3 inter quartile range.
Table 2. Summary of the metabolic data from patients who have attended the National AKU Centre for two years.
Baseline Day 4 3 Months 6 Months 1 Year 2 Years
u-HGA24 (mol/24 h) 20,557 5445 4120 3691 2295 1423 993 678 1029 817 1184 709
u-HGA/Creatinine (mol/mmol) 2264 867 378 272 213 133 88 48 94 65 107 73
u-Tyr24 (mol/24 h) 103 81 607 610 1010 732 1039 802 989 573 1071 726
u-Tyr/Creatinine (mol/mmol) 11.0 7.7 56.3 40.8 90.5 50.6 95.7 52.4 89.6 38.0 96.5 51.7
s-HGA (mol/L) 30.0 12.9 9.3 3.5 8.3 2.0 7.2 2.3 4.6 1.7 4.0 1.6
s-Tyr (mol/L) 42.0 13.3 373 87.1 611 165 603 124 689 119 594 184
s-NTBC (mol/L) Baseline 0.46 0.18 1.37 0.57 2.11 0.64 1.58 0.52 1.05 0.43
u: urine; s: serum; HGA: homogentisic acid; Tyr: tyrosine; NTBC: nitisinone.
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conﬁdence interval 18,446–22,669mol/24 h). At two
days after commencing NTBC, repeat urine measure-
ments showed that u-HGA24 decreased by 78.2%
(P< 0.0001), with an average excretion of 4120mol/
24 h. Three-month measurements revealed an 88.8%
reduction from baseline with average u-HGA24 of
2295mol/24 h. After three months, the increase to a
daily dose of 2mg resulted in an additional decrease to
95.4% at six months (n¼ 25, P¼ 0.0003) which has
remained steady at one year 94.8% (n¼ 27). Twenty-
six (compliant) patients have data at year two and still
maintain a decrease in u-HGA24 of 94.1% two years
post commencement of NTBC with an average u-
HGA24 of 1184mol/24 h.
Inherent issues with 24-h urine collections can occur
with incomplete collection, over-and under-collection
being the major problems. Relating the u-HGA to cre-
atinine (u-HGACr) demonstrated similar trends in redu-
cing u-HGA with baseline average 2264mol/mmol
creatinine reduced to 204mol/mmol at year two (a
94.0% decrease).
Serum tyrosine concentrations
At baseline, the mean serum tyrosine concentration was
42mol/L (range 20–82mol/L). The serum reference
interval in adults is approximately 21–87mol/L,19 so
all patients with one exception are within the normal
reference interval, which is characteristic of AKU. The
exception is the patient already on NTBC and who is
excluded from baseline statistics. Figure 2(b) and Table
2 demonstrate the trend of serum tyrosine pre and post
NTBC treatment. There was a rapid increase two days
after commencing NTBC, to a mean concentration of
373mol/L (range 249–546mol/L) with an average
eight-fold increase (range 278–1552%). Following the
rapid and signiﬁcant increase (P< 0.0001), there is an
additional signiﬁcant increase at three months
(P< 0.0001), between 6 months and 12 months
(P¼ 0.181) and 12 months and year two (P¼ 0.0366).
There is a large variation in tyrosine post-NTBC
among patients reﬂecting the dietary protein contribu-
tion (unpublished data) and potentially the diﬀering
responses to NTBC.
Urine tyrosine
At baseline, the average urine tyrosine excretion per
day (u-TYR24) was 103.1mol/24 h (range 15.7–
417mol/24 h). In relation to creatinine, the average
at baseline was 11.0mol/mmol (range 1.7–
38.8mol/mmol). With NTBC therapy, urine tyrosine
excretion increased with increasing serum tyrosine
(Table 2). Mean u-TYR24 was 607mol/24 h at day
four and at two years 1071mol/24 h, average six-
fold and 10-fold increases, respectively. Similar to
observations on serum tyrosine concentrations, a sig-
niﬁcant rise was seen comparing baseline to two days
post-commencing NTBC (P¼ 0.0001) and day 4 to
three months (P¼ 0.0375). There was no signiﬁcant dif-
ference between the average urine tyrosine concentra-
tions at subsequent monitoring periods.
Serum HGA
Serum HGA demonstrates a signiﬁcant decrease upon
commencing NTBC (Table 2). At baseline, there was a
wide range of baseline serum HGA concentrations,
similar to the range seen for urine HGA. Of note, all
patients had eGFR> 60ml/min/1.73m2 at baseline.
The average serum HGA at baseline was 30.0mol/L
(range 11.9–75.2mol/L). At two days after commen-
cing NTBC, the serum HGA has decreased by 64.0%
(P< 0.0001) and by three months 67.0% of baseline.
The NTBC was increased to 2mg daily at three
months which results in a further decrease in serum
HGA; at 6 months by 74.3% (n¼ 24), 12 months
82.7% (n¼ 26) and at 24 months 83.2% (n¼ 24). The
diﬀerence seen between 6 months and 12 months is sig-
niﬁcant (P< 0.0001) with no further signiﬁcant diﬀer-
ence seen comparing 12-month to 24-month time
periods.
No correlation was seen between serum and urine
HGA concentrations at baseline (R2¼ 0.1896 with
mol/24 h excretion; R2¼ 0.223 with mol/mmol
excretion).
Serum NTBC
Serum NTBC was measured and at three months fol-
lowing treatment with 2mg every other day, the mean
serum NTBC concentration was 1.37 0.57mol/L;
the six month time window reﬂects the increase in
dose to 2mg every day with an average of
2.11 0.64mol/L, a signiﬁcant increase (P¼ 0.0003).
NTBC concentrations then decrease signiﬁcantly
(P¼ 0.0056) at year one, compared with six months,
with an average of 1.58 0.52mol/L and by 24
months an average of 1.05mol/L (P¼ 0.0003) com-
pared with 12 months (Table 2). Evidence of non-com-
pliance was evident in one patient at six months and
one year, with NTBC< 0.2mol/L – these were
excluded from the signiﬁcance testing above. Of note,
the patient was compliant for year two assessment.
Adverse events
One adverse event occurred in a 21-year-old male who
developed tyrosine keratopathy and a skin rash at seven
weeks following 2-mg NTBC on alternative days.22
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NTBC was discontinued and the ocular symptoms, ker-
atopathy and rash all resolved. NTBC was recom-
menced at 2mg weekly which was tolerated with no
reoccurrence of the ocular or skin problems. His u-
HGA24 at baseline was 15,733mol/24 h, which
decreased to 80% of baseline at one year, with weekly
NTBC. Serum tyrosine at the time of the symptoms was
941mol/L and 582mol/L at year one.
Discussion
This is the ﬁrst longitudinal survey of the oﬀ-licence use
of NTBC for the treatment of AKU in a specialist hos-
pital setting. Herein we report the impact of NTBC
therapy on the tyrosine metabolic pathway over a
two-year period. Previous authors have reported on
the use of NTBC in treatment of AKU demonstrating
eﬃcacy of therapy,3,5,6,17 but only in a clinical trial set-
ting. Introne et al.5 demonstrated the utility of a 2mg
dose of NTBC over a three-year period. The method-
ology used for metabolite measurement resulted in 60%
of serum HGA measurements being undetectable and
therefore classiﬁed as in the reference range.
Sensitive and speciﬁc, LC-MS/MS methodology
developed at The Royal Liverpool University
Hospital4,20 has enabled the ﬁrst measurement of
serum and urine HGA in a non-AKU population.
Studies performed in-house have demonstrated that
serum HGA in non-AKU individuals is< 3.1mol/
L19 and as a consequence of our methodology, we
have measured serum HGA concentrations in 96% of
all samples. Therefore, a 2mg daily dose of NTBC is
not adequate to suppress serum HGA within the refer-
ence range, as previously thought. This is supported by
the recent clinical trial published3 where over a short
period of time (four weeks), a dose dependent decrease
was seen up to the highest tested dose of 8mg daily.
Urine HGA was also measurable in all cases and
again was not suppressed to the non-AKU reference
range of< 2.91mol/24 h19 on a daily 2mg dose of
NTBC. The lowest u-HGA concentration measured
was 43mol/24 h at year two. There was signiﬁcant
reduction in u-HGA24 and serum HGA concentrations
at six months when the NTBC dose was increased from
2mg on alternative days to daily, at three-month time
period. The reduction of urine HGA excretion by 94%
at year two supports previous studies where a> 95%
reduction was observed.5 To obtain a greater reduction,
it is suggested the NTBC dose may need to be
increased; however, the long-term safety and eﬃcacy
of this are currently unknown. The circulating HGA
concentrations (s-HGA) are of interest regarding the
pathological progression of AKU; urine HGA repre-
sents the amount ﬁltered and excreted, whereas serum
HGA is eﬀectively what is available for conversion to
the ochronotic pigment, via the benzoquinone pathway.
Within the NAC, the serum HGA concentrations are
reduced by an average 83% from baseline on a 2-mg
daily dose, suggesting there is still potential for pigment
deposition, albeit on a reduced scale. The rapid
decrease in both s-HGA and u-HGA seen at day 4
(post two doses of NTBC) has implications in cases
where a rapid decrease in HGA is required, such as
seen in haemolysis due to renal failure.23
Tyrosine concentrations increased dramatically upon
commencing NTBC which has previously been observed
in both AKU and in the treatment of HT1.16 However,
the dose of NTBC used in HT1 is 1–2mg/kg compared
with 2mg daily at the NAC. Due to the side eﬀects and
implications for development in children, serum tyrosine
is ideally maintained< 400mol/L,16 largely through
diet restriction. Non-compliance with protein restriction
in HT-1 has led to several reported ocular symptoms,
including corneal crystals and opacities24–26; similar cor-
neal opacities have been reported in AKU.5,22 In all
cases, the corneal opacities resolved upon cessation of
NTBC and normalization of tyrosine concentrations.
The mechanism for the keratopathy has not been fully
elucidated; however, there were patients in the NAC
who had higher serum tyrosine concentrations and did
not develop any ocular symptoms or side eﬀects, sug-
gesting a pre-disposition, independent of tyrosine con-
centrations. Diet restriction in adults is diﬃcult and
although patients at the NAC are advised about diet
and protein intake and food diaries are maintained, no
restriction is applied.
NTBC concentrations were determined when at
steady state, with a relatively long half-life of approxi-
mately 50 h; this is at a minimum, 10 days post com-
mencing treatment. Average serum concentrations were
2.11 0.64mol/L at six months with a signiﬁcant
decrease at one year to 1.58 0.52mol/L.
Therapeutic concentration in HT1 is 20–120mol/L
NTBC27;however, there is no suggested therapeutic
target for AKU. Previous studies have demonstrated
similar serum concentrations with 1.39 0.57mol/L
on a 1-mg dose twice daily17 and 2.22 0.54mol/L,
again on a 2mg daily dose.5 Although 2mg daily dose
is well tolerated, compliance has been an issue for a few
individuals. This is clearly determined by routine bio-
chemical measurements of tyrosine and HGA in both
serum and urine. Urine HGA returns to high baseline
concentrations and serum tyrosine to within the refer-
ence range. The signiﬁcant dose dependent decrease in
serum NTBC concentrations is not reﬂected by any
concurrent rise in serum HGA concentrations or nor-
malization of serum tyrosine; in fact, the serum HGA
signiﬁcantly decreases between 6 months and 12-month
monitoring periods. Analytical issues were excluded
with stability assays and re-analysis of earlier samples.
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Little is known about NTBC metabolism; it is known
to bind tightly to the HPPD-inhibitor complex with a
slow dissociation rate.28,29 Studies have demonstrated
dose proportional pharmacokinetics using daily 1mg to
8mg NTBC doses;30 however, this was only over a
four-week period. Metabolism of NTBC is via CYP
3A4 and certain medications are inducers or inhibitors
of this enzyme; there were no notable changes to the
medications of the patients in this cohort. Ongoing
studies into the metabolomic proﬁling of these patients
on NTBC therapy will hopefully aid in understanding
this change.
The survey of metabolic changes described herein
provides biochemical evidence for the safe and eﬃca-
cious use of NTBC therapy in lowering both urine and
serum HGA in the treatment of AKU, with oﬀ-licence
use of NTBC. Additional studies are on-going to deter-
mine if this will lead to a reduction in ochronosis, as
seen previously in a mouse model.8
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